Trademark: 79139500
Word
SELINCRO NALMEFENE
Status Date
Monday, April 10, 2023
Registration Number
4709949
Registration Date
Tuesday, March 31, 2015
Filing Date
Wednesday, April 10, 2013
Published for Opposition
Tuesday, January 13, 2015
Cancellation Date
Tuesday, April 11, 2023
41 Arranging and conducting educational seminars, conferences, symposiums, training workshops and courses; educational and training services in the form of educational seminars, conferences, symposia, education workshops and courses in the field of research and development, science, clinical tests, diagnostics, medicine, pharmaceuticals, disorders, diseases, treatments and prevention; educational and training services in the field of research and development, science, clinical tests, diagnostics, medicine, pharmaceuticals, disorders, diseases, treatments and prevention provided electronically, on-line, via cable or Internet or other electronic media; arranging and conducting of on-line educational forums, in the form of educational seminars, conferences, symposia, education workshops and courses; on-line training programs in the field of pharmaceutical research and development; providing non-downloadable on-line publications, namely, of books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of research and development, science, clinical tests, diagnostics, medicine, pharmaceuticals, disorders, diseases, treatments and prevention; on-line publication of medical data and analysis reports designed to provide patients and clients customized information, namely, medical dose, diagnosis, therapeutic issues and medical administration
9 Downloadable electronic publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of research and development, science, clinical tests, diagnostics, medicine, pharmaceuticals, disorders, diseases, treatment and prevention; data processing equipment and computers; computer hardware and software for information and information management for use of a web-based physical and psychological and neurological examination and assessment of patients and clients at a distance and at a clinic; application software for mobile devices, namely, applications with customized information regarding medicine dosage, medical diagnosis, therapy and medical information regarding central nervous system diseases and disorders; downloadable electronic publications in the nature of manuals in the field of central nervous system diseases and disorders
5 Pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of Alzheimer's disease and disorder, depression, psychosis, anxiety, epilepsy, multiple sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinson's disease and disorder, schizophrenia, bipolar disorder and disease, oncology, pain, alcohol dependency; vaccines; medicinal preparations for the treatment of central nervous system diseases and disorders and diagnostic preparations for medical purposes, all of the foregoing containing in whole or substantial part nalmefene
16 Printed instructional, educational and teaching materials in the field of research regarding depression; publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of research and development of central nervous system diseases and disorders and pharmaceuticals for the treatment and prevention of depression, medical science, clinical tests, diagnostics of central nervous system diseases and disorders, medicine, pharmaceuticals for the treatment of central nervous system diseases and disorders and the treatment and prevention of depression and central nervous system disorders and diseases
35 Retail and wholesale store services featuring pharmaceuticals; promotion and advertising services in the field of research and development, science, clinical tests, diagnostics, medicine, pharmaceuticals, disorders, diseases, treatments and prevention; provision of the aforementioned services on-line, via cable or Internet or other electronic media
44 Medical services; medical clinical services; medical treatment services; therapeutic treatment services; healthcare and medical services all related to central nervous system disorders, diseases and pharmaceuticals for the treatment thereof; providing medical and medicinal information in the field of diagnosis, medicine, pharmaceuticals, disorders, diseases, treatments and prevention; medical information services; diagnostic tests all in the field of central nervous system diseases and disorders
10 Medical test kits for the treatment and study of alcohol dependency; medical instruments and apparatus for the treatment and study of alcohol dependency
42 Providing on-line non-downloadable software for pharmaceutical research and development; scientific and technological research in the field of central nervous system disorders, diseases and the prevention thereof; medical research and tests; clinical research and tests; diagnostic research in the field of alcohol dependency; providing research and development services in the fields of medicine, science and clinical testing
The mark consists of the term "SELINCRO" over the term "NALMEFENE" is smaller type, all to the left of six vertical wavy lines that decrease in thickness and waviness from left to right.
Color is not claimed as a feature of the mark.
"NALMEFENE"
Oct 30, 2023
Notification Of Effect Of Cancellation Of Intl Reg E-Mailed
Oct 30, 2023
Death Of International Registration
Sep 26, 2022
Total Invalidation Processed By The Ib
Sep 1, 2022
Total Invalidation Of Reg Ext Protection Sent To Ib
Sep 1, 2022
Invalidation Processed
Jul 26, 2022
Total Invalidation Of Reg Ext Protection Created
Nov 26, 2021
Cancelled Section 71
Mar 31, 2020
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Aug 28, 2015
Final Decision Transaction Processed By Ib
Aug 11, 2015
Final Disposition Notice Sent To Ib
Aug 11, 2015
Final Disposition Processed
Jun 30, 2015
Final Disposition Notice Created, To Be Sent To Ib
Mar 31, 2015
Registered-Principal Register
Jan 15, 2015
Notification Processed By Ib
Jan 13, 2015
Official Gazette Publication Confirmation E-Mailed
Jan 13, 2015
Published For Opposition
Dec 24, 2014
Notification Of Possible Opposition Sent To Ib
Dec 24, 2014
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Dec 24, 2014
Notification Of Notice Of Publication E-Mailed
Dec 6, 2014
Law Office Publication Review Completed
Dec 5, 2014
Approved For Pub - Principal Register
Dec 5, 2014
Examiner's Amendment Entered
Dec 5, 2014
Notification Of Examiners Amendment E-Mailed
Dec 5, 2014
Examiners Amendment E-Mailed
Dec 5, 2014
Examiners Amendment -Written
Dec 5, 2014
Examiner's Amendment Entered
Dec 5, 2014
Notification Of Examiners Amendment E-Mailed
Dec 5, 2014
Examiners Amendment E-Mailed
Dec 5, 2014
Examiners Amendment -Written
Jul 28, 2014
Notification Of Non-Final Action E-Mailed
Jul 28, 2014
Non-Final Action E-Mailed
Jul 28, 2014
Non-Final Action Written
Jul 28, 2014
Previous Allowance Count Withdrawn
Jun 12, 2014
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 12, 2014
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 13, 2014
Withdrawn From Pub - Og Review Query
May 31, 2014
Law Office Publication Review Completed
May 31, 2014
Approved For Pub - Principal Register
May 24, 2014
Teas/Email Correspondence Entered
May 24, 2014
Correspondence Received In Law Office
May 15, 2014
Assigned To Lie
May 3, 2014
Teas Response To Office Action Received
Jan 6, 2014
Refusal Processed By Ib
Dec 17, 2013
Application Filing Receipt Mailed
Dec 13, 2013
Non-Final Action Mailed - Refusal Sent To Ib
Dec 13, 2013
Refusal Processed By Mpu
Dec 13, 2013
Non-Final Action (Ib Refusal) Prepared For Review
Dec 12, 2013
Non-Final Action Written
Dec 11, 2013
Assigned To Examiner
Dec 11, 2013
New Application Office Supplied Data Entered
Dec 9, 2013
Limitation From Original Application Entered
Dec 6, 2013
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
